Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth P Lerner

Showing results (101-110 of 294) with videos related to

Pageof 30
Sort By:
The Journal of Urology|November 25, 2003
The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancerShahrokh F Shariat, Roberto Casella, Mara A Monoski, et al.
Urologia Internationalis|February 23, 2010
Accuracy of the extent of bladder cancer nodal metastases found at pelvic lymphadenectomy at the time of cystectomy: relation to primary tumor stageFarhang Rabbani, Cheryl Lee, Sam S Chang, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Tumor Subtyping: Making Sense of Heterogeneity with a Goal Toward TreatmentJoshua J Meeks, Gottfrid Sjödahl, Seth P Lerner, et al.
The Journal of Urology|February 11, 2003
Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladderShahrokh F Shariat, Ja-Hong Kim, Gustavo E Ayala, et al.
European Urology|March 16, 2010
Prevention and management of complications following radical cystectomy for bladder cancerNathan Lawrentschuk, Renzo Colombo, Oliver W Hakenberg, et al.
The Journal of Urology|February 8, 2002
Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancerBen Andrews, Shahrokh F Shariat, Ja-Hong Kim, et al.
Urology|May 9, 2003
Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladderShahrokh F Shariat, Mara A Monoski, Ben Andrews, et al.
The Journal of Urology|January 10, 2004
Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancerShahrokh F Shariat, Roberto Casella, Seyed M Khoddami, et al.
Bladder Cancer (Amsterdam, Netherlands)|February 3, 2017
Utility of Clinical Risk Stratification in the Selection of Muscle-Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy: A Retrospective Cohort StudyFriedrich-Carl von Rundstedt, Douglas A Mata, Oleksandr N Kryvenko, et al.
European Urology|July 8, 2010
A critical analysis of orthotopic bladder substitutes in adult patients with bladder cancer: is there a perfect solution?Wassim Kassouf, Richard E Hautmann, Bernard H Bochner, et al.
Pageof 30

Showing results (101-110 of 294) with videos related to

Sort By:
Pageof 30
The Journal of Urology|November 25, 2003
The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancerShahrokh F Shariat, Roberto Casella, Mara A Monoski, et al.
Urologia Internationalis|February 23, 2010
Accuracy of the extent of bladder cancer nodal metastases found at pelvic lymphadenectomy at the time of cystectomy: relation to primary tumor stageFarhang Rabbani, Cheryl Lee, Sam S Chang, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Tumor Subtyping: Making Sense of Heterogeneity with a Goal Toward TreatmentJoshua J Meeks, Gottfrid Sjödahl, Seth P Lerner, et al.
The Journal of Urology|February 11, 2003
Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladderShahrokh F Shariat, Ja-Hong Kim, Gustavo E Ayala, et al.
European Urology|March 16, 2010
Prevention and management of complications following radical cystectomy for bladder cancerNathan Lawrentschuk, Renzo Colombo, Oliver W Hakenberg, et al.
The Journal of Urology|February 8, 2002
Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancerBen Andrews, Shahrokh F Shariat, Ja-Hong Kim, et al.
Urology|May 9, 2003
Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladderShahrokh F Shariat, Mara A Monoski, Ben Andrews, et al.
The Journal of Urology|January 10, 2004
Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancerShahrokh F Shariat, Roberto Casella, Seyed M Khoddami, et al.
Bladder Cancer (Amsterdam, Netherlands)|February 3, 2017
Utility of Clinical Risk Stratification in the Selection of Muscle-Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy: A Retrospective Cohort StudyFriedrich-Carl von Rundstedt, Douglas A Mata, Oleksandr N Kryvenko, et al.
European Urology|July 8, 2010
A critical analysis of orthotopic bladder substitutes in adult patients with bladder cancer: is there a perfect solution?Wassim Kassouf, Richard E Hautmann, Bernard H Bochner, et al.
Pageof 30